Skip to main content

Table 5 Overall treatment satisfactiona (ITT population)

From: Final results from IMPROVE: a randomized, controlled, open-label, two-arm, cross-over phase IV study to determine patients’ preference for everolimus in combination with exemestane or capecitabine in combination with bevacizumab in advanced HR-positive, HER2-negative breast cancer

 

First-line therapy

Second-line therapy

Arm A (N = 39)

Arm B (N = 38)

Arm A (N = 17)

Arm B (N = 19)

Satisfied

30 (76.9%)

24 (63.2%)

10 (58.8%)

11 (57.9%)

Not satisfied

5 (12.8%)

7 (18.4%)

3 (17.6%)

5 (26.3%)

Missing

 

2 (5.3%)

1 (5.9%)

2 (10.5%)

p-value

0.3832

 

0.6243

 
  1. aTreatment satisfaction was evaluated in week 12 of each treatment phase, assessed by the Treatment Satisfaction Questionnaire. Second-line: Due to small n, the p-value of the asymptotic chi-square test may not be valid. The p-value of the corresponding exact test was 0.6968. Missing: Item was not answered or not evaluable. Discrepancies between the sum of answers reported and the total n are due to patients, who did not answer the whole questionnaire